Madrigal Pharmaceuticals, Inc.
DE ˙ DB ˙ US5588681057
413,00 € ↓ -12,70 (-2,98%)
2026-06-01
DEL PRIS
SecurityDE:YDO1 / Madrigal Pharmaceuticals, Inc.
InstitutionState Street Corp
Latest Disclosed Ownership700,739 shares
Ownership 3.55%
State Street Corp ownership in YDO1 / Madrigal Pharmaceuticals, Inc.

2024-01-22 - State Street Corp has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 700,739 shares of Madrigal Pharmaceuticals, Inc. (DE:YDO1). This represents 3.55 percent ownership of the company. In their previous filing dated 2023-02-02 , State Street Corp had reported owning 1,260,993 shares, indicating a decrease of -44.43 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2024-01-22 2024-01-22 13G/A 1,260,993 700,739 -44.43 3.55 -51.83
2023-02-02 2023-02-02 13G 1,260,993 7.37

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F MADRIGAL PHARMACEUTICALS COM 558868105 609,525 26,522 4.55 319,068 -6.02 0.0110
2026-02-13 2025-12-31 13F MADRIGAL PHARMACEUTICALS COM 558868105 583,003 -75,094 -11.41 339,506 12.48 0.0114
2025-11-14 2025-09-30 13F MADRIGAL PHARMACEUTICALS COM 558868105 658,097 -32,618 -4.72 301,843 44.40 0.0105
2025-08-14 2025-06-30 13F MADRIGAL PHARMACEUTICALS COM 558868105 690,715 -67,796 -8.94 209,038 -16.80 0.0078
2025-05-15 2025-03-31 13F MADRIGAL PHARMACEUTICALS COM 558868105 758,511 -22,777 -2.92 251,242 4.21 0.0104
2025-02-14 2024-12-31 13F MADRIGAL PHARMACEUTICALS COM 558868105 781,288 -106,464 -11.99 241,082 27.96 0.0095
2024-11-14 2024-09-30 13F MADRIGAL PHARMACEUTICALS COM 558868105 887,752 143,038 19.21 188,399 -9.70 0.0077
2024-08-14 2024-06-30 13F MADRIGAL PHARMACEUTICALS COM 558868105 744,714 119,776 19.17 208,639 25.02 0.0091
2024-05-15 2024-03-31 13F MADRIGAL PHARMACEUTICALS COM 558868105 624,938 -75,801 -10.82 166,883 2.93 0.0075
2024-02-14 2023-12-31 13F MADRIGAL PHARMACEUTICALS COM 558868105 700,739 58,473 9.10 162,137 72.86 0.0079
2023-11-14 2023-09-30 13F MADRIGAL PHARMACEUTICALS COM 558868105 642,266 98,507 18.12 93,797 -25.33 0.0052
2023-08-14 2023-06-30 13F MADRIGAL PHARMACEUTICALS COM 558868105 543,759 23,945 4.61 125,608 -0.26 0.0066
2023-05-15 2023-03-31 13F MADRIGAL PHARMACEUTICALS COM 558868105 519,814 -741,179 -58.78 125,930 -65.59 0.0071
2023-05-15 2022-12-31 13F/A-99 MADRIGAL PHARMACEUTICALS COM 558868105 1,260,993 294,352 30.45 366,003 482.60 0.0215
2023-05-15 2022-12-31 13F MADRIGAL PHARMACEUTICALS COM 558868105 1,260,993 294,352 366,003 0.0215
2022-11-15 2022-09-30 13F MADRIGAL PHARMACEUTICALS COM 558868105 966,641 141,334 17.13 62,822 6.34 0.0040
2022-08-15 2022-06-30 13F MADRIGAL PHARMACEUTICALS COM 558868105 825,307 59,428 7.76 59,075 -21.39 0.0035
2022-05-16 2022-03-31 13F MADRIGAL PHARMACEUTICALS COM 558868105 765,879 167,131 27.91 75,148 48.11 0.0037
2022-02-14 2021-12-31 13F MADRIGAL PHARMACEUTICALS COM 558868105 598,748 -159,867 -21.07 50,738 -16.18 0.0024
2021-11-15 2021-09-30 13F MADRIGAL PHARMACEUTICALS COM 558868105 758,615 136,153 21.87 60,530 -0.17 0.0032
2021-08-16 2021-06-30 13F MADRIGAL PHARMACEUTICALS COM 558868105 622,462 36,712 6.27 60,634 -11.50 0.0032
2021-07-09 2021-03-31 13F/A-1 MADRIGAL PHARMACEUTICALS COM 558868105 585,750 -57,665 -8.96 68,515 -4.21 0.0039
2021-05-17 2021-03-31 13F MADRIGAL PHARMACEUTICALS COM 558868105 585,750 -57,665 68,515 0.0039
2021-02-16 2020-12-31 13F MADRIGAL PHARMACEUTICALS COM 558868105 643,415 212,171 49.20 71,528 39.70 0.0044
2020-11-10 2020-09-30 13F MADRIGAL PHARMACEUTICALS COM 558868105 431,244 -173,991 -28.75 51,202 -25.30 0.0035
2020-08-14 2020-06-30 13F MADRIGAL PHARMACEUTICALS COM 558868105 605,235 128,455 26.94 68,543 115.34 0.0050
2020-06-19 2020-03-31 13F/A-1 MADRIGAL PHARMACEUTICALS COM 558868105 476,780 18,402 4.01 31,830 -23.78 0.0028
2020-05-11 2020-03-31 13F MADRIGAL PHARMACEUTICALS COM 558868105 476,780 18,402 31,830 2,795.3149
2020-02-06 2019-12-31 13F MADRIGAL PHARMACEUTICALS COM 558868105 458,378 -43,887 -8.74 41,763 -3.56 0.0029
2019-11-14 2019-09-30 13F MADRIGAL PHARMACEUTICALS COM 558868105 502,265 -115,481 -18.69 43,305 -33.12 0.0032
2019-08-14 2019-06-30 13F MADRIGAL PHARMACEUTICALS COM 558868105 617,746 51,384 9.07 64,746 -8.74 0.0048
2019-05-15 2019-03-31 13F MADRIGAL PHARMACEUTICALS COM 558868105 566,362 -34,065 -5.67 70,943 4.82 0.0055
2019-02-12 2018-12-31 13F MADRIGAL PHARMACEUTICALS COM 558868105 600,427 172,158 40.20 67,680 -26.20 0.0062
2018-11-09 2018-09-30 13F MADRIGAL PHARMACEUTICALS Common equity shares 558868105 428,269 85,763 25.04 91,704 -4.28 0.0070
2018-08-14 2018-06-30 13F MADRIGAL PHARMACEUTICALS Common equity shares 558868105 342,506 -117,865 -25.60 95,800 78.18 0.0080
2018-05-15 2018-03-31 13F MADRIGAL PHARMACEUTICALS Common equity shares 558868105 460,371 390,618 560.00 53,766 739.83 0.0046
2018-02-14 2017-12-31 13F MADRIGAL PHARMACEUTICALS Common equity shares 558868105 69,753 24,933 55.63 6,402 218.19 0.0005
2017-11-14 2017-09-30 13F MADRIGAL PHARMACEUTICALS Common equity shares 558868105 44,820 11,650 35.12 2,012 273.28 0.0002
2017-08-14 2017-06-30 13F MADRIGAL PHARMACEUTICALS Common equity shares 558868105 33,170 33,170 539 0.0000
2016-11-14 2016-09-30 13F MADRIGAL PHARMACEUTICALS Common equity shares 558868105 0 -79,573 -100.00 0 -100.00
2016-08-12 2016-06-30 13F MADRIGAL PHARMACEUTICALS Common equity shares 558868105 79,573 79,573 21 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.